問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

List

1394Cases

2018-01-15 - 2029-06-30

Phase III

Active
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB(T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    KEYTRUDA

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting4Sites

2017-05-01 - 2019-12-31

Phase III

Completed
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Alzheimer’s Disease

  • Condition/Disease

    Alzheimer’s Disease

  • Test Drug

    RVT-101

Participate Sites
2Sites

Terminated1Sites

Study ended1Sites

黃錦章
Linkou Chang Gung Medical Foundation

2026-03-15 - 2032-10-25

Phase III

Active
ROSETTA Lung-202: A randomized, double-blind, Phase 3 trial comparing pumitamig monotherapy with pembrolizumab as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer and PD-L1 expression ≥ 50%.

  • Condition/Disease

    Comparison of Pumitamig monotherapy versus Pembrolizumab as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer and PD-L1 expression ≥ 50%.

  • Test Drug

    BMS-986545

Participate Sites
5Sites

Recruiting5Sites

2026-03-16 - 2034-01-30

Phase III

Not yet recruiting
Efficacy, safety, and pharmacokinetics of once-weekly subcutaneous cagrilintide 2.4 mg as monotherapy and in combination with subcutaneous semaglutide 2.4 mg (CagriSema) for weight management in overweight or obese children and adolescents.

  • Condition/Disease

    Obesity

  • Test Drug

    Cagrilintide CagriSema Semaglutide

Participate Sites
4Sites

Recruiting4Sites

2019-11-01 - 2024-05-13

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2019-11-30 - 2026-09-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2019-12-01 - 2027-04-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2019-12-01 - 2024-12-31

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2019-12-01 - 2026-07-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting3Sites

2020-01-01 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5 140
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB